SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around its long-term development on the Solana blockchain and celebrates its presence on the Jupiter Strict List. Token holders express bullish sentiment and emphasize community collaboration with other meme coins like $BROKE and $WAGMI, while playfully engaging with the project's UpDog joke meta.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as the community rallies around a shared vision of success and unity, with some anticipating a CoinMarketCap listing. Community members express excitement for the project's potential, noting its strong presence across multiple platforms and comparing it to early $DOGE.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its cultural significance and roots in the crypto space. Active discussion points include references to its community, website, and links to DEX screeners. The coin aims to blend cryptocurrency with cannabis culture, fostering a community-driven approach.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as community members speculate about a potential manufacturing partnership or agreement with Tesla, especially with Tesla expected to make an announcement this week. The air taxi maker recently participated in an airshow and X users have also speculated that Tesla’s teaser could hint at its entry into the eVTOL space, potentially creating a $9 trillion market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members speculate about potential catalysts and buyout rumors, with some suggesting a potential acquisition by Eli Lilly. Discussions highlight the company's pipeline, particularly VK2735, and its potential in the consolidating metabolic disease market. The community is also focused on the upcoming maintenance dosage trial and earnings call, anticipating updates on expenses and Phase 3 enrollment.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions about its partnerships, particularly with NVIDIA and Amazon, and its potential in the quantum computing space. The community is debating its high valuation relative to revenue, with some viewing it as a potential short squeeze while others express concerns about a possible bubble. Bullish sentiment is fueled by collaborations and potential government contracts, while bears point to insider selling and dilution.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending after reports surfaced about potential US government interest and investment in its Greenland rare earths mine, sparking excitement among investors. The community is actively discussing the implications of government backing, potential for growth, and comparisons to similar situations with other companies in the sector. Bullish sentiment is high, with many anticipating further gains and long-term potential for the stock in the critical minerals market.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the critical minerals sector gains momentum, with community members pointing to potential cup and handle formations and anticipating a move towards double digits. Indonesia's suspensions on critical minerals mining have also put a spotlight on the deep sea mining sector. Bullish sentiment is building, with many expressing conviction in TMC's long-term potential and awaiting key catalysts like NOAA approval.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The "Rage Guy" meme token, $RAGE, is trending as its community rallies around a shared identity and anticipates a moonshot. Fuelled by the power of collective emotion, the project is actively building a strong community and encouraging each other to "RAGE harder" and unite to create a movement. The community views dips as opportunities and welcomes newcomers to join before a potential surge.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MicroStrategy) is trending as Bitcoin flirts with all-time highs, yet some traders express frustration that $MSTR isn't keeping pace, leading to discussions about potential dilution and market manipulation. Despite the concerns, many community members remain bullish, anticipating a breakout and eyeing price targets like $400. The stock's correlation with Bitcoin's movements and its potential for a short squeeze are also key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?

Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Matches Q2 Earnings Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and +1.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences drew heightened retail investor chatter on Wednesday after the FDA awarded Rare Pediatric Disease designation to its gene editing therapy PBGENE-DMD, which targets duchenne muscular dystrophy (DMD) treatment.The stock surged as much as 9% during regular trading but reversed course to close down 7.2% at $4.24, and extended losses in after-hours trading, slipping 3.5%.The designation, which is intended to provide incentives for the development of drugs and biologics for serious and life-threatening conditions that predominantly affect individuals under age 18, could provide Precision with a priority review voucher (PRV) upon approval of the drug.PRVs can be redeemed for accelerated FDA review of a different drug or sold to other companies, creating potential for non-dilutive capital.Precision’s chief development and business officer, Cindy Atwell, said the designation supports the potential of PBGENE-DMD to deliver a “meaningful improvement and durable functional benefit” for up to 60% of patients.PBGENE-DMD is a first-in-class in vivo gene editing therapy that uses the company’s proprietary Arcus platform, designed to excise exons 45–55 of the dystrophin gene using two Arcus nucleases delivered in a single Adeno-associated virus (AAV).&nbsp;The one-time treatment aims to restore a near full-length, naturally produced dystrophin protein, considered functional in humans.In preclinical studies, PBGENE-DMD showed:<ul class="todo-list"><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Significant, durable functional improvements in a humanized DMD mouse model</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Restoration of dystrophin production in key muscle types, including cardiac and skeletal muscle</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Editing of satellite muscle stem cells, believed to be important for long-term durability</label></li></ul>&nbsp;The company is currently completing final IND-enabling toxicology studies and said it expects to begin clinical testing in 2026.Precision also said that its Arcus platform enables precise, defined therapeutic gene edits using a small, structurally distinct nuclease, supporting gene insertion, elimination, and excision.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,025% surge in 24-hour message volume.One user pointed to Precision’s cash reserves of over $80 million and described the current setup as a “good risk-reward,” suggesting the downside appears limited while the potential upside could be unlimited.<stembedurl>https://stocktwits.com/pinkal/message/619015289</stembedurl>Another user, reflecting on a much higher cost basis from early 2021, assessed whether the current dip might offer a fresh buying opportunity.<stembedurl>https://stocktwits.com/foxhedgehog/message/618993420</stembedurl>The stock has declined 9.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

The FDA designation could make Precision eligible for a valuable Priority Review Voucher, while preclinical data showed strong dystrophin restoration across key muscle groups.

Equity

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, including gene elimination...

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Precision Biosciences Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$5.44
Prev Close	$5.42
Open	$5.44
Dividend Yield	0.00%
50-Day Moving Average	$4.90
Beta	0.86
Avg. Volume	90,239.14
PE Ratio	-0.62

52-Week High	$9.55
52-Week Low	$3.61
Market Capitalization	$64.12M
EPS (Annual)	$1.04
Price to Book	1.86
Revenue Per Employee	$636,074.07
Enterprise Value/EBITDA	N/A

DTIL
Precision Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DTIL News

DTIL Precision Biosciences Inc